Signature_________________________Date________
HARRY A. CROFT, MD
Distinguished Life Fellow - American Psychiatric Association
8038 Wurzbach Rd., Suite 570
San Antonio, Texas 78229
210-692-1222
Email: hacmd@aol.com
Website: www.drcroft.com
PRESENT POSITIONS
Medical Director, San Antonio Psychiatric Research Center, Founded 1986, San Antonio, Texas
Private Psychiatry Practice, The Croft Group, PA, Founded 1976, San Antonio, Texas
Medical Director, HealthyPlace.com , 2007-Present
Host Weekly HealthyPlace TV Webcast, March 2009-March 2010
OTHER PRESENT WORKS (book):
Harry Croft & Chrys Parker, authors: I ALWAYS SIT WITH MY BACK TO THE WALL: Managing
Traumatic Stress and Cpmbat PTSD Through the RECOVER Approach for Veterans and Families,
Stillpoint Media, 2011.
PERSONAL INFORMATION
Born: July 2, 1943; Houston, Texas
Married: 1964 to present with 2 children born in 1966, 1977, and 3 granddaughters
WORK HISTORY
Private Clinical Psychiatric Practice: 1976 to present
Medical Director, SA Psychiatric Research Center, 1985-present
Medical Director, HealthyPlace.com, 2007 - present
Military: 1973 to 1976 - Major, Army Medical Corps, Brooke Army Medical Center, San Antonio,
Texas; Chief, Mental Health Clinic; Medical Director, Drug & Alcohol Program;
Lecturer, Academy of Health Sciences; Recipient, US Army Meritorious Service Medal
EDUCATION
University of Texas Medical Branch, Galveston, Texas
1970 - 1973 - Residency, General Psychiatry
1969 - 1970 - Partial Residency, Obstetrics & Gynecology
1964 - 1968 – MD degree
Brackenridge Hospital, Austin, Texas
1968 - 1969 - Internship, General Rotating
Southern Methodist University, Dallas, Texas
1964 – BS Degree in Biology
CERTIFICATIONS & LICENSURE
DISTINGUISHED LIFE FELLOW, American Psychiatric Association, 2003
FELLOW, American Psychiatric Association, 1993
Diplomate in Psychiatry, American Board of Psychiatry & Neurology, 1979
Diplomate, American Board of Addiction Medicine, 2009
Certified Addictionist, American Society of Addiction Medicine, 1990
Diplomate in Sex Therapy, American Assoc. of Sex Educators, Counselors & Therapists, 1976
Medical License, Texas State Board of Medical Examiners, 1968, D4968
SPECIAL TRAINING IN SEXUALITY
Masters & Johnson Institute, 1973
Stan Kaplan, Ph.D., Albuquerque, New Mexico, 1972
National Sex Forum, San Francisco, California, 1972
MEMBERSHIP IN PROFESSIONAL SOCIETIES
American Medical Association, Texas & Bexar County Branches (AMA)
American Psychiatric Association, Texas & Bexar County Branches (APA)
American Society of Addiction Medicine (ASAM)
American Association of Sex Educators, Counselors & Therapists (AASECT)
American Society for Clinical Hypnosis (ASCH)
American Society for Clinical Psychopharmacology (ASCP)
Titus Harris Psychiatry Society
National Medical Speakers Association (NSA)
National Association of Physician Broadcasters (NAPB)
American Academy of Radio and Television Health Communicators
Society for the Scientific Study of Sexuality (SSSS)
International Society for the Study of Women’s Sexual Health (ISSWSH)
International Society for the Study of Trauma
HOSPITAL STAFF ACCREDITATION
Southwest Texas Methodist Hospital (Active Staff), 1976-2000
Southwest Texas Methodist Hospital (Courtesy Staff), 2000-present
ACADEMIC TEACHING EXPERIENCE
CME Faculty: Medical World Conferences, Duke PsychCME, Primary Care Network, Center for
Medical Knowledge, Intellyst, Medical Knowledge (Psych Update, and PriMed) (To Present)
Teaching Consultant, USAF Psychiatry Training Program, Texas Academy of Family Practice
Wilford Hall Medical Center, 1973 - 1976
Clinical Assistant Professor, Psychiatry & OB-GYN,
University of Texas Health Science Center at San Antonio, 1973 - 1976
Assistant Professor, Health Science,
Baylor University, Waco, Texas, 1975 - 1976
Instructor, Academy of Health Sciences, Fort Sam Houston, Texas, 1973 - 1976
HONORS
DISTINGUISHED LIFE FELLOW, American Psychiatric Association, 2003
Recipient of Physician's Recognition Award, AMA
Recipient of The Meritorious Service Medal, U.S. Army
Recipient of Special President's Award, The American Psychiatric Association, 1991
2
Recipient of THE WELBY AWARD FOR MEDIA EXCELLENCE, The Academy of
Radio and TV Health Communicators
Recipient of The Jules Bergman Award (BROADCASTER OF THE YEAR),
The National Association of Physician Broadcasters, 1995
Recipient of Media Award, The American Psychiatric Association, 1996
Recipient of NATIONAL MEDIA AWARD, The National Mental Health Association, 1996
Heart Survivor Honoree, The American Heart Association, 2003
Biography: WHO’S WHO IN AMERICA (since 1976), Who's Who in Professional Speaking
MEDIA WORK
Weekly medical/psychiatric consultant, Trey Ware Show, KTSA am 55 radio (morning
drive) 2005-present
Psychiatric Correspondent, KMOL TV 4 (NBC Affiliate), January 1999 to March 2000
Monthly guest consultant SA Living 2000-present
Psychiatric Correspondent with weekly features at 5pm & 10pm on KENS TV 5
(CBS affiliate), January 1988 to January 1999
Radio Show Host, PSYCH TALK, 2 hour live talk show, KENS Radio, January 1996 to December
1998
Selected to be Psychiatric Correspondent, VOICE OF AMERICA, daily news segment, 1997,
psychiatric Correspondent on Kaleidoscope, National TV Morning Magazine, PAX TV, 2002
ABC TV affiliate (KSAT TV12), San Antonio regular (weekly) live and taped segments,
5pm News, September 1986 to January 1988
Appearances on: CBS Early Morning with Bryant Gumble, CNN News, Sonya Live
Interviews:
USA Today, Chicago Tribune, Bloomberg, CBS, CNN Radio, Texas Radio Network,
The New York Times, The Associated Press, The Readers Digest, Better Homes &
Gardens, National Public Radio, Canadian Broadcasting, Radio Interviews (100)
including Philadelphia, Chicago, Houston, Dallas, Miami, and Los Angeles
MAJOR WORKSHOPS & PRESENTATIONS
The American Medical Association
The American Psychiatric Association
The American Society of Clinical Psychopharmacology
The European College of Neuropsychopharmacology
The Society of Biological Psychiatry
The National Society for the Scientific Study of Obesity
The American College of Obstetrics & Gynecology
The American Association of Marriage & Family Counselors
The Southern Medical Association
The Texas Medical Association
The National Army Chaplain's Association
The National Army Social Work Association
Retail Pharmacists of America
The American Farm Bureau
Jewish Women’s International Conferences
Lectures Given to Psychiatrists, Primary Care Physicians, Neurologists, Mental Health
Professionals, OB-Gyns, and other professional groups in: ALL OF THE 50 United
States, & London, Paris, Amsterdam, San Juan, St Thomas, Monterrey, Toronto, Madrid
Member of Distinguished Faculty for the following CME providers:
PsychCME (Duke Psychiatry), Primary Care Network (PCN), Medical
World Conferences, Prime MD Net, Texas Association of Family Practice
3
Curriculum development: Primary Care Network
Lecture TopicsPhysicians & MH Professionals:
Managing.Unipolar to Bipolar Depression Spectrum
Depression-Long Term Treatment & Challenges
Advances in Antidepressant Treatment
Evaluation and Treatment of Adult ADHD,
Treatment of Anxiety Disorders,
Alcohol and Drug Abuse & Dependence Disorders
Treatment of Medication Induced Sexual Dysfunction
Treatment of Erectile.Dysfunction,
Female Sexual Health
Management of Insomnia
General Public:
Depression: Finding Light at the End of the Tunnel,
Dealing with Anxiety, Lessons from the Heart (about
heart disease), Keeping the Flame Alive (improving
relationships and sex), Adult AHD, Substance Abuse
PAPERS, POSTERS, PRESENTATIONS:
Clayton, A, Croft HA, Handiwala L, “Antidepressants and Sexual Dysfunciton: Mechanisms and Clinical
Implications,” Journal of Sex and Marital Therapy, 2012 (in print).
Leibowitz M, Croft H et al, “The Safety and Tolerability Profile of Vilazodone, A Novel Antidepressant for
the Treatment of Major Depressive Disorder, Psychopharmacology Bulletin, Vol 44, No. 3, 2012
Croft,H, “ Viibryd (vilazodone hcl): A New Option for the treatment of adults with MDD: An overview of
Prescribing Information,” Product Theater Presentation, Annual Meeting of the American
Psychiatric Association, Honolulu, May 2011
Croft, H et al, “The Safety and Tolerability Profile of Vilazodone in Patients with Major Depressive
Dissorder,” Poster Presentation at the US Psychiatric Congress, San Diego, 11/2010.
Sheehan, DV, Croft, HA et al. “Extended Release Trazodone in Major Depressive
Disorder: A Randomized, Double-blind, Placebo-controlled Study,” Psychiatry
(Edgmont), 2009 May; 6(5): 20-33.
Croft,H, Montejo,AL, Salazar-Fraile,J. “Bupropion: Tolerability and Safety,” Actas Esp Psiquiatr (SPAIN)
2008:36 (Supp 4).
Nurnberg, GN, Hensley, PJ, Croft, HA, Debattista, CA, et al “Sildenafil Treatment of Women with
Antidepressant-Associated Sexual Dysfunction: A Randomized Clinical Trial,” JAMA, July
23/30, 2008 (Vol 300): No 4, 395-404
Seagraves, Clayton, Croft, et al “A Multicenter Double Blind Placebo Controlled Study of Bupropion XL in
Females with Orgasm Disorders” Poster at Psychiatric Congress 06, New Orleans, 11/06.
Croft,HA “Physician Handling of Prescription Stimulants (CME Article)”, Pediatric Annals 35:8, 557-562,
August, 2006.
Clayton, A, Croft HA et al, “Bupropion XL Compared with Escitalopram: Effects on Sexual Functioning
and Antidepressant Efficacy in Two Randomized, Double-Blind, Randomized Clinical Studies
Journal of Clinical Psychiatry 67:5 735-746, May, 2006.
4
Croft, HA “Physician Handling of Prescription Stimulants (CME Article)” Psychiatric Annals 35:3 221-226
2005
Wornock JK, Clayton AH, Croft HA, Segraves RT, Biggs CF. Comparison Of Androgens IWomen With
Hypoactive Sexual Desire Disorder: Combined Oral Contraceptive Pill Users vs
NoCombined Oral Contraceptive Pill Users. Oral presentation at the International Society for The
Study of Women's Sexual Health (ISSWSH) Annual Meeting, Atlanta, GA, October 28-31, 2004.
Journal of Sex & Marital Therapy (In Print, 06)
Seagraves, RT, Clayton, A, Croft, HA et al, “Bupropion Sustained Release for the Treatment of
Hypoactive Sexual Desire Disorder in Premenopausal Women,” J Clin Psychopharmacology;
2004, 243) 339-342.
Seagraves, RT, Clayton, A, Croft, HA et al, “Multicenter Study of Bupropion in Female Hypoactive
Sexual Desire Disorder, “ Presented at2003 Annual Meeting of the International Society for the
Study of Women’s Sexual Health, Amsterdam, the Netherlands. October, 2003.
Labbate, L, Croft,HA, and Oleshansky, MA, “Antidepressant-Related Erectile Dysfunction:Management
via Avoidance, Switching Antidepressants, Antidotes, and Adaptation,” J Clin Psychiatry, 2003;
64 (10): 11-19.
Nurnberg HG, Hensley PL, Croft HA, Fava M, Warnock JK, Pain S. Sildenafil citrate treatment for SRIassociated female sexual dysfunction. Accepted for poster presentation at the 156 th
American Psychiatric Association Annual Meeting, May 17-22, 2003, San Francisco , CA.
Clayton, A, Pradko, J, Croft, HA, et al. “Prevalence of Sexual Dysfunction Among Newer
Antidepressants,” J Clin Psychiatry, 2002; 63 (4): 357-366
Nurnberg H, Hensley P, Fava M, Croft HA, Gelenberg A, Wornock J, Shabsogh R, “Sildenafil for
Serotonin Reuptake Inhibitor-Antidepressant Associated Female Sexual Dysfunction,” Presented at
New Clinical Drug Evaluation Unit (NCDEU) annual meeting, Boca Raton, 2002
Croft, HA, Houser, T, Jamerson B, Leadbetter R, “Effect on Body Weight of Bupropion SR in Patients with
Major Depression Treated for 52 weeks,” Clinical Therapeutics,24(4),April 2002
Segraves, R.T., Croft, H.A., Kavoussi, R., Ascher, J., Batey, S., et al.
“Bupropion sustained release for the treatment of hypoactive sexual desire disorder in nondepressed
women.” Journal of Sex and Marital Therapy, 2001; 27 (3) : 301-316
Croft, HA, “The Patient with Depression: Managing Compliance and Side Effects” Profiles in Depression,
(Oxford Institute for Continuing Education), March 2002
Segraves, R.T., Croft, H.A., Kavoussi, R., Ascher, J., Batey, S., et al.
“Bupropion sustained release for the treatment of hypoactive sexual desire disorder in nondepressed
women,” Journal of Sex and Marital Therapy, 27(3): 303-316. 2001 May-June
Croft, HA Settle, E, Houser T Batey, SR et al. “A Placebo Controlled comparison of the antidepressant
efficacy and effects on sexual functioning of sustained-release bupropion and sertraline,” Clinical
Therapeutics, 21(4): 643-658, 1999 April
Croft HA, Asher J, Batey S et al. “A comparison of burprion SR, Sertraline and placebo in depressed
outpatients,” Biological Psychiatry, 45(8 supp) 75s, 1999
Croft H, Houser T Leadbetter R, Jamerson B, Metz A. Effects of bupropion sr on weight in the long-term
treatment of depression. Obesity Research, 8 (Suppl. 1:10S), 2000
Croft H, Houser TL, Leadbetter R, Jamerson B, Metz A. Effects of bupropion sr on weight in the long term
treatment of depression. Biological Psychiatry 49(Suppl 8:36s) 2001
Croft, H.A., Batey, S., Ascher, J., et al.
5
“A Comparison of the Effects of Bupropion SR and Sertraline on Sexual Functioning in Depressed
Outpatients”, Poster Presented at Annual Meetings of: American Society of Clinical
Psychopharmacology, St. Thomas, Virgin Islands, February 1999; Society of Biological Psychiatry,
Washington, DC, May 1999; The American Psychiatric Association, Washington, DC, May 1999,
European College of Neuropsychopharmacology, London, UK, September 1999
Kaats, G.R., Keith, S.C., Croft, H.A., Pullin, D., Squires, W., Wise, J.A.
“Dietary Supplements and Behavior Modification Plan to Improve the Safety and Efficacy of
Pharmacotherapy”, Advances in Therapy, 1998; 15: 165-177
Kaats, G.R., Wise, J.A., Blum, K., Morin, R.J., Adelman, J.A., Craig, J., Croft, H.A.
“The Short –Term Therapeutic Efficacy of Treating Obesity with a Plan of Improved Nutrition and
Moderate Caloric Restriction”, Current Therapeutic Research, 1996; 51: 261-274
Szekely, B. & Croft, H.A.
"Effect of Naproxen Sodium on Perimenstrual Headache and Other Perimenstrual Symptoms:
A Double -Blind, Placebo Controlled Study," American Journal of Gynecologic Health,
Vol.V, #4,July/August 1991
Szekely, B. & Croft, H.A.
"Prophylactic Effects of Naproxen Sodium on Perimenstrual Headache," Cephalalgia, International
Journal of Headache, Vol. 19, Supp. 10, 1989
Szekely, B. & Croft, H.A.
"Descriptive Characteristics of Women with Perimenstrual Headache," Headache, The Journal
of Head & Face Pain, Vol. 29, #5, 1989
Levinson, A.J. & Croft, H.A.
"Patients' Sexual Problems-Aspects of Physicians' Qualifications & Management," The Journal
of Reproductive Medicine, Vol. 18, #1, January 1977
Croft, H.A.
"How to Refer Your Patients to a Psychiatrist Without Hurting Their Feelings," Resident & Staff
Physician Medical Times, August, 1976
Croft, H.A.
"Managing Common Sexual Problems," Post Graduate Medicine, 4 Part Series, 1976:
"Sexual History Taking," Vol. 60, #3, Sep. 1976., "Causes of Sexual Dysfunction," Vol. 60, #4,
Oct.1976., "A Multilevel Treatment Model - Levels 1 & 2," Vol. 60, #5, Nov. 1976.,
"A Multilevel Treatment Model - Levels 3 & 4," Vol. 60, #6, Dec. 1976
Croft, H.A., et al.
"Viewpoints," Medical Aspects of Human Sexuality, 129: 57-62, 1976
Croft, H.A.
"The Sexual Information Examination," Journal of Sex & Marital Therapy, Vol. 1, #4, 319-325, 1976
Croft, H.A.
"A Human Sexuality Course in the Military," Military Medicine, 141:104-108, 1976
Powell, L.C., Blakeney, P., & Croft, H.A.
"Rapid Treatment Approach to human sexual inadequacy," American Journal of Obstetrics
Gynecology,119:89, 94, May 1974
Dawson, E.B., Croft, H.A., Clark, R.R., & McGanity, W.J.
"Study of Nine Cation Levels in Term Placentas -- Changes Associated with Toxemia of
Pregnancy and Fetal Maturity," American Journal of Obstetrics & Gynecology, 103:8, April 1969
Dawson, E.B., Croft, H.A., Clark, R.R., & McGanity, W.J.
"Study of Seasonal Variations in Nine Cations of Normal Term Placentas, "American Journal
of Obstetrics & Gynecology, 102:3, October 1968
6
RESEARCH
Trimel Biopharma SRL, Phase II-XXX-X-XXX-XXXX-XX- “A placebo-controlled, randomized,
double-blind, parallel-group dose finding trial to evaluate the efficacy and safety of XXX-X Intranasal
Testosterone Gel in pre-menopausal women with acquired Female Orgasmic Disorder.” -2012
Takeda XX XXXXXXX_XXX- “A Randomized, Double-Blind, Parallel-Group, Active-Controlled,
Flexible-Dose Study Evaluating the Effect of XX XXXXXXX vs Escitalopram on Sexual Functioning
in Adults With Well-Treated Major Depressive Disorder Experiencing Selective Serotonin Reuptake
Inhibitor-Induced Sexual Dysfunction.” -2011
Otsuka XXX-XX-XXX- “A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial
of the Safety and Efficacy of Fixed-dose XXX-XXXXX as Adjunctive Therapy in the Treatment of
Adults with Major Depressive Disorder, the Pyxis Trial.” -2011
Forest XXX-XX-XX- “A Double-blind, Placebo-Controlled, Fixed-Dose Study of XXXXXXXXX XX in
Patients With Major Depressive Disorder.” -2011
Bristol-Myers Squibb XXXXX-XXX- “A Multicenter, Double-Blind, 58-week Rollover Study to assess
the Safety and Tolerability of BMS-XXXXXX in Patients with Treatment Resistant Major
Depression.”-2011
Bristol-Myers Squibb XXXXX-XXX- “A Multicenter, Randomized, Double-blind, Active-Controlled
Study of the Efficacy and Safety of Flexibly-Dosed BMS-XXXXXX in Patients with Treatment
Resistant Major Depression.” -2011
Takeda XX XXXXXXX_XXX- “A Phase 3, Long-Term, Open-Label, Flexible-Dose, Extension Study
Evaluating the Safety and Tolerability of XX XXXXXXX (XX and XX mg) in Subjects With Major
Depressive Disorder.” -2010
Takeda XX XXXXXXX_XXX- “A Phase 3, Randomized, Double-Blind, Parallel-Group, PlaceboControlled, Duloxetine-Referenced, Fixed-Dose Study Comparing the Efficacy and Safety of 2 Doses
(XX and XX mg) of XX XXXXXXX in Acute Treatment of Adults With Major Depressive Disorder.”2010
Forest XXX-XX-XX- “A Multicenter, Randomized, Double-blind, Placebo-Controlled, RelapsePrevention Study With XXXXX XX in Patients With Major Depressive Disorder.” -2010
Boehringer Ingelheim Protocol XXX.XXX- “A twenty-eight week, open-label, safety, extension trial of
XXXXXXXXX XXX milligrams daily in premenopausal and naturally postmenopausal women with
hypoactive sexual desire disorder in North America.” -2010
Boehringer Ingelheim Protocol XXX.XXX- “A twenty-four week, randomized, double-blind, placebo
controlled, safety and efficacy trial of XXXXXXXX (XXX milligrams) administered orally once daily in
premenopausal women with hypoactive sexual desire disorder in the United States.”- 2009
Boehringer Ingelheim Protocol XXX.XXX- “A 12-week, randomized, double-blind, placebo-controlled,
Phase III safety trial of XXXXXX tablets (XXX milligrams daily) in women taking a XXXXXXXXXXX
or XXXXXXXXXXXX with decreased sexual desire distress.” – 2009
Forest XXX-XX-XX- “A Double-Blind, Placebo-Controlled Study of XXXXXXXX (XXX-XXX) as
Adjunctive Therapy in Major Depressive Disorder.” -2009
7
Forest XXX-XX-XX- “A Long-Term, Open-label Extension Study of XXXXX XX in Adult Patients With
Major Depressive Disorder.”- 2009
Forest XXX-XX-XX- “A Double-blind, Placebo-Controlled, Fixed-Dose Study of XXXXX XX in
Patients with Major Depressive Disorder.” -2009
GlaxoSmithKline XXXXXXXXX- “A Randomized, Double-Blind, Placebo-Controlled Study Evaluating
the Efficacy and Safety of XXXXXXX in Subjects with Major Depressive Disorder.” -2009
Eli Lilly XXX-XX-XXXX(X)- “A Randomized, Double-Blind Comparison of XXXXXXXXX and Placebo
and Long Term Treatment with XXXXXXXXX in Adult Patients with Major Depressive Disorder.” 2009
Takeda XX XXXXXXX_XXX- “A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled,
Fixed-Dose Study Comparing the Efficacy and Safety of a Single Dose of XX XXXXXXX in Acute
Treatment of Adults with Generalized Anxiety Disorder.” -2008
Forest XXX-XX-XX- “A Long-Term, Open-Label Extension Study of XXXXXXX in Adult Patients with
Major Depressive Disorder."- 2008
Forest XXX-XX-XX- “A Double-Blind, Fixed-Dose Study of XXXXXXX in Adult Patients with Major
Depressive Disorder.”- 2008
Synosia Therapeutics XXXXXX-XXXX- “A Multi-center Randomized, Double-Blind, PlaceboControlled, Phase 2, Exploratory Study to Evaluate the Effect of XXXXXXXX on Anxiety in Patients
with Moderate to Severe Generalized Anxiety Disorder.”- 2008
Sepracor XXX-XXX- “A Double-Blind, Randomized, Placebo Controlled, Multi-Center Study
Examining the Efficacy and Safety of XXX-XXXXXX in Subjects with Generalized Anxiety Disorder.”2007
PGxHealth XXXX-XX-XX-XX- “A One Year Label Study Assessing the Safety and Tolerability of
XXXXXX in Patients with Major Depressive Disorder.”- 2007
Labopharm XXXXXXX- “A Randomized, Double-blind, Two-arm Study Comparing the Efficacy and
Safety of XXXXXXXXXX and Placebo in the Treatment of Unipolar Major Depressive Disorder.”2007
Bristol-Myers Squibb XXXXXXXX- “A Multicenter, Randomized, Double-Blind, Placebo and
Escitalopram Controlled Trial of the Safety and Efficacy of XXXXXXXX in the Treatment of
Outpatients with Major Depressive Disorder”-2007
Boehringer Ingelheim Protocol XXXXXXX- “A twelve month, open-label, safety trial of XXXXXXX 50
milligrams to XXX milligrams daily in women with Hypoactive Sexual Desire Disorder.”-2007
Boehringer Ingelheim Protocol XXXXXXXX-“A Twenty Four Week, Randomized, Double-Blind,
Placebo-Controlled, Safety and Efficacy Trial of XXXXXXXX XX mg Twice Daily and XX mg Once
and Twice Daily in Premenopausal Women With Hypoactive Sexual Desire Disorder in North
America.” - 2006
Astrazeneca Protocol XXXXXXX-“A Multicenter, Double-blind, Randomized, Parallel-group,
Placebo-controlled Phase III Study of the Efficacy and Safety of XXXXXXXX as Monotherapy in the
treatment of Patients with Major Depressive Disorder.” -2006
AstraZeneca Protocol XXXXXXX-“A Multicenter, Randomized, Double-blind, Parallel-group,
Placebo-controlled Study of the Efficacy and Safety of XXXXXXX Compared with Placebo in the
Treatment of Generalized Anxiety Disorder.”- 2006
8
Sanofi-aventis Protocol XXXXXXX-“A Comparison of XXXXXX vs. Placebo in the Treatment of
Insomnia Associated with Newly Diagnosed Major Depressive Disorder (MDD) or Untreated MDD
Relapse, When Used Concomitantly with XXXXXXX.”-2006
Sanofi-aventis Protocol XXXXXXX-“A Comparison of XXXXXX vs. Placebo in the Treatment of
Insomnia Associated with Generalized Anxiety Disorder (GAD) when used concomitantly with
XXXXXX.”-2006
Avera Protocol XXXXXX-XXX-“A Phase2, Double-B, Placebo-Controlled Trial to Investigate the
Safety and Efficacy of XXXXX in Subjects with Social Anxiety Disorder”-2006
Sepracor Protocol XXX-XXX-“The Efficacy of XXXXXXXXX mg as Adjunctive Therapy in Subjects
with Insomnia Related to Generalized Anxiety Disorder”-2005
Forest Protocol XXX-XX-XX – “Fixed Dose Comparison of XXXXXXXXXXXX Combination in Adult
Patients with Major Depressive Disorder.” - 2005
Cephalon Protocol XXXXX/XXXX/XX/XX – “A 12-Month, Open-Label, Flexible-Dosage Study to
Evaluate the Safety and Efficacy of XXXXXXXX© Treatment (up to XXmg/day) in Adults With
Generalized Anxiety Disorder” – 2005
Cephalon Protocol XXXXX/XXXX/XX/XX – “A 10-Week, Randomized, Double-Blind, PlaceboControlled, Parallel-Group Study to Evaluate the Efficacy and Safety of XXXXXXXX® at X, X, and
XXmg/day in the Treatment of Adults With Generalized Anxiety Disorder.” - 2004
GlaxoSmithKline Protocol XXXXXX – “A Twelve-week, Multi-center, Randomized, Double-blind,
Double-dummy, Parallel-group, Active controlled, Escalating Dose Study to Compare the Effects on
Sexual Functioning of XXXXXXXXX XXXXXXXXXXXX Extended-release (XXXXXXXXXX™ XX,
XXXmg/day) and Extended-release XXXXXXXXXX (XXXXXXX XX, XX-XXXmg/day) in Subjects
with Major Depressive Disorder.” – 2004
Organon Protocol X-XXXX – “A Multicenter, randomized, double-blind, double dummy, group
comparative trial to compare the effects of XXXXXXXX and XXXXXX continuous combined
XXXXXXXXX/XXXXXXXXXXXXXX on the vaginal bleeding pattern, sexual desire and arousal in
post menopausal women with sexual dysfunction.” – 2004
Segraves, MD Protocol #XXXX-XXX. – “ A Multicenter, Double-Blind, Placebo-Controlled study of
XXXXXXXXX XX in females with orgasm disorder.” - 2004
Fabre-Kramer Protocol – “A Double-Blind, Multicenter, Randomized, Placebo-Controlled Efficacy
and Safety Study of XXX XXXXX XX in Subjects with Major Depressive Disorder.” - 2003
Eli Lilly Protocol XXX-XX-XXXX – An Open-Label Study to Evaluate the Efficacy and Safety of
XXXXXXXXX Administered “On Demand” to Men of Various Populations with Erectile
Dysfunction. – 2003
GlaxoSmithKline Protocol XXX-XXXXX – “A Randomized, Double-Blind, Parallel-Group, placeboControlled Fixed Dose Study Evaluating Efficacy and Safety of XXXXXXXXXX XX in Elderly
Outpatients Diagnosed with Major Depressive Disorder.” - 2003
GlaxoSmithKline Protocol XXXXXXXX – “A Multicenter, Double-Blind, Randomized, PlaceboControlled Comparison of the Effects of Sexual Functioning of Extended-Release XXXXXXXXX
XXXXXXXXXXXX )XXX-XXXmg) and XXXXXXXXXXXX (XX-XXmg) in Outpatients with
Moderate to Severe Major Depression over and Eight-Week Treatment Period.” - 2003
GlaxoSmithKline Protocol XXXXXXXXX – “A Multicenter, Randomized, Double-Blind, ParallelGroup, Placebo-Controlled, Flexible-Dose Study Evaluating Efficacy, Safety, and Tolerability of
9
Once Daily Oral XXXXXXXX (XX-XX-XXmg) Versus Placebo in Subjects with Major Depressive
Disorder Over an Eight-Week Treatment Period.” – 2003
Merck Protocol XXX-XX – “A Double-Blind, Multicenter, Placebo-Controlled Study of X-XXXXXX
Gel Extrusion Module (XXX) X.X mg b.i.d to X.X mg b.i.d Versus XXXXXXXXX in the Treatment
of Outpatients with Generalized Anxiety Disorder.” - 2002
Pharmacia & Upjohn Protocol XXXX-XXXX-XXX –“A 12 week randomized Double-Blind
XXXXXXX-and XXXXXXXXX-Controlled Fixed-Dose Parallel-Group Multicenter Study for
Generalized Anxiety Disorder”. – 2002
Pharmacia & Upjohn Protocol XXXX-XXXX-XXX – “ A 5 month open-label study on
XXXXXXXXXXX in the treatment of Generalized Anxiety Disorder”. - 2002
GlaxoSmithKline Protocol XX-XXXXXX-XXXX – “A Randomized, Double-Blind, Parallel-Group,
Placebo-Controlled Study Evaluating Efficacy and Safety of XX-XXXXXXX (XXmg/day and
XXmg/day) and XXXXXXXXXX (XXmg/day) in Patients with Major Depressive Disorder”. – 2001
Merck Protocol XXX-XX –“A Worldwide, Multicenter, Double-Blind, Parallel, Acitive-Controlled, Long
Term Safety Study of XX-XXXX in Outpatients with Major Depressive Disorder”. – 2001
Ortho-McNeil Protocol XXXX-XXX – “A 12-week, Multi-center, randomized, double-blind, placebo
controlled, parallel group study of XXXXXX-XX in subjects with Bipolar Disorder Type 1”. -2001
Pfizer Protocol XXX-XXX-XXX – “A 6-week, Double-Blind, Randomized, Multicenter, Fixed-Dose,
Placebo-Controlled Study of XXXXXXXXX, Dosed Twice a Day in Patients With Generalized Anxiety
Disorder”. - 2001
Investigator Initiated study – “Double-Blind Placebo Controlled Study of XXX-XXXXXXX for
Serotonergic Antidepressant Associated Sexual Dysfunction in Women”. 2001
Investigator Initiated study on a new therapy for HSDD. -2001
Merck – “A Double-Blind, Multicenter, Placebo and Active-Controlled Acute and Extension Study of
XX-XXXX in the Treatment of Patients with Major Depressive Disorder With Melancholic Features”.
2001
An Eli Lilly study on a new medication for Major Depression. - 2000
Novartis Protocol XXXXXXX- “A Double-Blind, Randomized, Parallel-Group, Active And Placebo
Controlled Study to Evaluate Safety and Efficacy of XXXXXXX in Patients with Social Phobia. – 2000
TAP Pharmaceutical Products Inc. Protocol XXX-XXX-XX-XXX – “A Phase II Randomized,
Multicenter, Placebo and Active Controlled Study of XXXX XXX-XXX In Subjects With Major
Depressive Disorder.” – 2000
Parke-Davis Protocol XXXX-XXX – “An 8-Week, Double-Blind, Randomized, Multicenter, FlexibleDose, Placebo-Controlled Study of XXXXXXXXX in Patients With Panic Disorder.” - 2000
Parke-Davis Protocol XXXX-XXX – “A 6-Week, Double Blind, Randomized, Multicenter, FlexibleDose, Placebo-Controlled Study of XXXXXXXX In Patients With Generalized Anxiety Disorder –
2000
A Eli Lilly study on a combination therapy for treatment resistant depression” – 1999
A Eli Lilly study on a new medication for depression” – 1999
A Eli Lilly study on a pharmacological treatment of antidepressant associated sexual dysfunction” –
1999
10
Pharmacia & Upjohn Protocol X-XXXX-XXXX – “XXXXXXXXXX vs. Placebo Double-Blind
Treatment of Major Depressive Disorder Resistant to XXXXXXXXXX” – 1999
Pharmacia & Upjohn Protocol XXXXXXXXXXX-XXX – “Open-Label XXXXXXXXXX Rescue and
Continuation Therapy” – 1999
Glaxo Wellcome Protocol XXXXXXXX - “A Randomized, Multicenter, Double-Blind, PlaceboControlled, Fixed-Dose 7-Week Evaluation of the Efficacy and Safety of XXXXXXXXXXX in
Treatment of a Major Depressive Episode in Unipolar Depressed Patients” - 1998
SmithKline Beecham Protocol XXX XXXXXX- “A Randomized, Double-Blind, Placebo-Controlled,
Flexible Dosage Trial to Evaluate the Efficacy and Tolerability of XXXXXXXXXX in Patients with
Generalized Anxiety Disorder” - 1998
Glaxo Wellcome Protocol XXXXXXXX - “A Multicenter, Double-Blind, Placebo-Controlled
Comparison of the Safety and Efficacy and Effects on Sexual Functioning of XXXXXXXXXX
(XXXXXXXXX XXXXXXXXXXXXX) XXXXXXXXX XXXXXXX (XX) and XXXXXXXXXX in
Outpatients with Moderate to Severe Recurrent Major Depression” - 1998
Glaxo Wellcome Protocol XXXXXXXX - “A Multicenter Single-Blind Study of XXXXXXXXXX
(XXXXXXXXX XXXXXXXXXXXXX) XXXXXXXXX XXXXXX (XX) in Non-Depressed Females with
Hypoactive Sexual Desire Disorder (HSDD)” - 1998
Forest Laboratories, Inc. and Parke-Davis - “XXXXXX (XXXXXXXXX XXX) Clinical Experience
Trial (Easy Access to Symptom Evaluation).” - 1998
Pharmacia & Upjohn Protocol XX-XXXX-XXX - “XXXXXXXXXX (XXX_XXXXXXX) Versus
Placebo and XXXXXXXXXX in a Controlled, Randomized, Double-Blind, Multicenter Study of
Treatment in Major Depressive Disorders” - 1998
Glaxo Wellcome Protocol No. XXXXXXXX - “A Multicenter Placebo-Controlled Study of
XXXXXXXXXX (XXXXXXXXX XXXXXXXXXXXXX) XXXXXXXXX XXXXXXX (XX) for the
Prevention of Relapse/Recurrence in Subjects Whose Depression Responded to Treatment With
XXXXXXXXXX SR” - 1998
Pfizer, Inc. Protocol No. XXX-XXX - “A Multicenter, Randomized, Open Label, Comparative, Study of
the Safety, Tolerability and Efficacy of XXXX XXXXXXXXXXX for Long Term Treatment of Subjects
with Acute Migraine” - 1997
Pfizer, Inc. Protocol No. XXX-XXX - “A Multicenter, Double-Blind, Randomized, Placebo Controlled,
Parallel Group Study of the Efficacy and Safety of Escalating the Dose of XXXX XXXXXXXXXX in
Subjects with Acute Migraine” - 1997
Pfizer, Inc./Eisai America, Inc. Protocol No. XXXXX-XXXX-XXX - “An Open Label, Multicenter
Clinical Trial Evaluating the Safety and Efficacy of XXXXXXXX XXXXXXXXXXXXX (XXXXX) in
Patients with Alzheimer’s Disease” - 1996 - 1997
Glaxo Wellcome Protocol No. XXXXXXXX - “A Multicenter, Double-Blind, Placebo-Controlled
Comparison of the Effects on Sexual Functioning of XXXXXXXXXX (XXXXXXXXX XXX)
XXXXXXXXX XXXXXXX and XXXXXXXXXXX in Outpatients with Moderate to Severe Recurrent
Major Depression” - 1996 - 1997
Bristol-Myers Squibb Protocol No. XXXXX-XXX XXXXXXXX X- "A Prospective, Multicenter, OpenLabel Study of XXXXXX (XXXXXXXXX XXX) Augmentation Therapy of XXXXXXX (XXXXXXXXXX
XXX) in the Management of Patients with Symptoms of Depression in General Psychiatric Practices"
- 1994 - 1995
Bristol-Myers Squibb Protocol No. XXXXX-XXX - "A Prospective, Multicenter, Open-Label Study of
XXXXXXX (XXXXXXXXXX) in the Management of Patients with Symptoms of Depression in
General Psychiatric Practices" - 1994 - 1995
11
Burroughs Wellcome Protocol XXX - "The Safety and Efficacy of XXXXXXXXXX XXXXXXXX
XXXXXXX and XXXXXXXXXX in Depressed Outpatients" - 1994
Burroughs Wellcome Protocol XXX - "Safety Surveillance Study for XXXXXXXXXX XXXXXXXXX
XXXXXXX" - 1993-1994
SmithKline Beecham Protocol XXX - "A Randomized, Comparative, Open-Label Study of
XXXXXXXXXX in the Treatment of Depression as Used in a Clinical Practice Setting" - 1993
Pfizer Protocol X-XXXX - "Multicenter Trial to Evaluate the Efficacy and Safety of XXXXXXXXXX in
the Treatment of Major Depression" - 1992
Burroughs Wellcome Protocol XXX - "Prospective Open Evaluation of the Seizure Incidence with
XXXXXXXXX XXXXXXXXXXXXX" - 1988
Merrell-Dow Protocol - XXXXXXXXX: Smoking Termination Aid, 1984
AV MATERIALS
BOOK IN PROGRESS : “I Sit With My Back to the Wall: Voices of Trauma:Voices of Healing.” A book for Combat
Veterans and those who care about and for them….Written with Rev Dr. Chrys Parker
Videotape for Physicians
Recognizing Sexual Dysfunction in Depression
Self Help Videotapes
Headache, Depression, Anxiety, Alcoholism, Divorce, Sexual Abuse, Helping Your Child
Succeed, Panic Disorder, Menopause, Attention Deficit Disorder, Men Who Batter, Affairs,
Alcoholism in Elderly, High-tech Psychiatry, Sandwich Generation, Keeping
Romance Alive, Elderly Alcoholism, Teen-age Drinking
One hour PBS (KLRN TV) specials: Teen-age Drinking, Depression, Anxiety and Panic Disorder,
Alzheimer’s Disease
Human Sexuality
Four part audio tape cassette series published by Audio-Digest and The American
Psychiatric Association
Sex and Recovery, A videotape distributed by Hazelden Recovery Center
Modern Day ECT
Videotape produced by Education Department, Southwest Texas Methodist Hospital,
San Antonio, Texas, 1980
VD: It's Your Problem
16 mm and Videotape, Academy of Health Sciences Television Division,
H.A. Croft, Technical Advisor and Producer
Contraception: Alternatives for Today
16 mm Film and Videotape (used in Army), Winner of four first place awards, Academy
of Health Sciences Television Division, H.A. Croft, Technical Advisor and Producer
12
POTENTIAL CONFLICT OF INTEREST INFORMATION
HARRY CROFT, M.D.
2011
RESEARCH GRANTS to Croft Group Research Center
Boehringer-Ingelheim, Bristol-Myers-Squibb, Cephalon, Forest, GlaxoSmithKline, Eli Lilly, Labopharm,
Merck, Organon, Otsuka, Pfizer, Sanofi-Aventis, Takeda
SPEAKING HONORARIA in past 5 years:
Astra Zeneca, Bristol-Myers Squibb, Forest, GlaxoSmithKline, Eli Lilly, Angenlini-Labopharm, Pfizer, SanofiAventis, Wyeth
CONSULTANT in past 5 years:
Forest, GlaxoSmith Kline, Eli Lilly, Pfizer
ADVISORY BOARD in past 5 years:
GlaxoSmithKline, Lilly, Pfizer
OTHER FINANCIAL INTEREST (or Family):
None
Last revision: 07/27/2011
13